JP7046016B2 - Ｈｅｒｖ－ｅ反応性ｔ細胞受容体および使用方法 - Google Patents

Ｈｅｒｖ－ｅ反応性ｔ細胞受容体および使用方法 Download PDF

Info

Publication number
JP7046016B2
JP7046016B2 JP2018567933A JP2018567933A JP7046016B2 JP 7046016 B2 JP7046016 B2 JP 7046016B2 JP 2018567933 A JP2018567933 A JP 2018567933A JP 2018567933 A JP2018567933 A JP 2018567933A JP 7046016 B2 JP7046016 B2 JP 7046016B2
Authority
JP
Japan
Prior art keywords
cells
nucleic acid
seq
cell
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018567933A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019522984A5 (enExample
JP2019522984A (ja
Inventor
リチャード ダブリュー． チャイルズ，
マイケル アイ． ニシムラ，
エレナ エー． チェルカソワ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of JP2019522984A publication Critical patent/JP2019522984A/ja
Publication of JP2019522984A5 publication Critical patent/JP2019522984A5/ja
Application granted granted Critical
Publication of JP7046016B2 publication Critical patent/JP7046016B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/56—Kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Prostheses (AREA)
JP2018567933A 2016-06-30 2017-06-30 Ｈｅｒｖ－ｅ反応性ｔ細胞受容体および使用方法 Active JP7046016B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662357265P 2016-06-30 2016-06-30
US62/357,265 2016-06-30
PCT/US2017/040448 WO2018006054A1 (en) 2016-06-30 2017-06-30 Herv-e reactive t cell receptors and methods of use

Publications (3)

Publication Number Publication Date
JP2019522984A JP2019522984A (ja) 2019-08-22
JP2019522984A5 JP2019522984A5 (enExample) 2020-08-06
JP7046016B2 true JP7046016B2 (ja) 2022-04-01

Family

ID=59381696

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018567933A Active JP7046016B2 (ja) 2016-06-30 2017-06-30 Ｈｅｒｖ－ｅ反応性ｔ細胞受容体および使用方法

Country Status (9)

Country Link
US (1) US11779603B2 (enExample)
EP (1) EP3478711B1 (enExample)
JP (1) JP7046016B2 (enExample)
KR (1) KR102461926B1 (enExample)
CN (1) CN109415429B (enExample)
AU (1) AU2017286982B2 (enExample)
DK (1) DK3478711T3 (enExample)
NZ (1) NZ749585A (enExample)
WO (1) WO2018006054A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111100185A (zh) * 2018-10-26 2020-05-05 上海锐赛生物技术有限公司 Ct-rcc herv-e来源的ctl表位肽、肽库及其应用
CN113710697A (zh) 2019-03-15 2021-11-26 美国政府(由卫生和人类服务部的部长所代表) 嵌合衔接子和激酶信号传导蛋白及其在免疫疗法中的用途
WO2021194495A1 (en) 2020-03-26 2021-09-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cd28h domain-containing chimeric antigen receptors and methods of use
WO2023044304A1 (en) 2021-09-15 2023-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
WO2025064539A1 (en) * 2023-09-19 2025-03-27 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Herv-e antibodies and methods of their use
CN118620059B (zh) * 2024-02-21 2025-08-15 北京永泰瑞科生物科技有限公司 一种t细胞抗原受体及其制备方法和其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012038055A1 (en) 2010-09-20 2012-03-29 Unicell Gmbh Antigen-specific t cell receptors and t cell epitopes
JP2013176373A (ja) 2007-03-23 2013-09-09 Shizuoka Prefecture Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
EP1224291A1 (en) * 1999-10-28 2002-07-24 Universite De Geneve Multiple sclerosis-related superantigen
DE10019075B4 (de) * 2000-04-18 2007-01-18 Vision 7 Gmbh Verwendung von CD34 oder einem davon abgeleiteten Polypeptid als Zell-Oberflächen- bzw. Gentransfer-Marker
US7820174B2 (en) * 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use
WO2007109583A2 (en) * 2006-03-17 2007-09-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject
SG173997A1 (en) * 2006-07-21 2011-09-29 Univ California Human endogenous retrovirus polypeptide compositions and methods of use thereof
CN101528926A (zh) 2006-08-18 2009-09-09 肿瘤疗法科学股份有限公司 过表达reg4或kiaa0101的癌症的治疗或预防
JO3257B1 (ar) * 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013176373A (ja) 2007-03-23 2013-09-09 Shizuoka Prefecture Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子
WO2012038055A1 (en) 2010-09-20 2012-03-29 Unicell Gmbh Antigen-specific t cell receptors and t cell epitopes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DEBETS RENO，TCR-ENGINEERED T CELLS TO TREAT TUMORS: SEEING BUT NOT TOUCHING?，SEMINARS IN IMMUNOLOGY，2016年03月17日，VOL:28, NR:1，PAGE(S):10 - 21，http://dx.doi.org/10.1016/j.smim.2016.03.002
KIRSCH ILAN，T-CELL RECEPTOR PROFILING IN CANCER，MOLECULAR ONCOLOGY，2015年09月15日，VOL:9, NR:10，PAGE(S):2063 - 2070，https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528728/pdf/MOL2-9-2063.pdf
YOSHIYUKI TAKAHASHI，REGRESSION OF HUMAN KIDNEY CANCER FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION IS ASSOCIATED WITH RECOGNITION OF AN HERV-E ANTIGEN BY T CELLS，JOURNAL OF CLINICAL INVESTIGATION，米国，2008年03月03日，VOL:118,NR:3，PAGE(S):1099-1109，https://www.jci.org/articles/view/34409/pdf

Also Published As

Publication number Publication date
JP2019522984A (ja) 2019-08-22
KR20190058389A (ko) 2019-05-29
US20190231821A1 (en) 2019-08-01
DK3478711T3 (da) 2022-12-12
US11779603B2 (en) 2023-10-10
KR102461926B1 (ko) 2022-11-02
AU2017286982B2 (en) 2022-10-13
NZ749585A (en) 2023-02-24
CN109415429A (zh) 2019-03-01
CN109415429B (zh) 2023-04-28
WO2018006054A1 (en) 2018-01-04
EP3478711B1 (en) 2022-10-12
AU2017286982A1 (en) 2019-01-17
EP3478711A1 (en) 2019-05-08

Similar Documents

Publication Publication Date Title
JP7479082B2 (ja) 免疫機能制御因子をコードする核酸、及びがん抗原を特異的に認識する細胞表面分子、ｉｌ－７及びｃｃｌ１９を発現する免疫担当細胞の作製方法
JP7046016B2 (ja) Ｈｅｒｖ－ｅ反応性ｔ細胞受容体および使用方法
US11111301B2 (en) T cell modification and use thereof
AU2018360599A1 (en) Process for generating therapeutic compositions of engineered cells
US20160235787A1 (en) Epitope Spreading Associated with CAR T-Cells
JP2019525898A (ja) ヒト白血球抗原拘束ガンマデルタｔ細胞受容体及びその使用方法
CN113677353A (zh) 修饰细胞的扩增及其用途
US12139523B2 (en) Anti-LMP2 TCR-T cell therapy for the treatment of EBV-associated cancers
WO2009139413A1 (ja) サイトカイン誘導キラー細胞含有細胞集団の製造方法
US20230048361A1 (en) Methods of culturing t cells and uses of same
US20240058447A1 (en) Use of fusion constructs for il-2 independent t cell therapy
CN116254230A (zh) 用于制备和扩增通用型人源化抗cd19 car-nk细胞的方法及其用途
US12453763B2 (en) Human vaccine compositions and methods for treating leukemia
WO2024222701A1 (zh) 一种t细胞受体及其用途
WO2024243428A2 (en) Use of fusion constructs for cell therapy
CN119604524A (zh) 用于癌症疗法的工程化t细胞受体构建体
JP2025541604A (ja) リンパ球の拡大
HK40050970A (en) Anti-lmp2 tcr-t cell therapy for the treatment of ebv-associated cancers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200623

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220322

R150 Certificate of patent or registration of utility model

Ref document number: 7046016

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250